Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
HST Global Inc (PK) | HSTC | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.08 | 1.08 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.1425 - 1.15 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 1.08 | USD |
HST Global Inc (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.67M | 5.25M | - | 0 | -146k | -0.03 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HST Global (PK) News
Date | Time | Source | News Article |
---|---|---|---|
5/16/2024 | 15:56 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
8/11/2023 | 11:09 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HSTC Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.10 | 1.10 | 1.08 | 1.08 | 300 | -0.02 | -1.82% |
1 Month | 0.94 | 1.11 | 0.81055 | 1.05 | 562 | 0.14 | 14.89% |
3 Months | 1.14 | 1.15 | 0.5001 | 0.7611672 | 1,529 | -0.06 | -5.26% |
6 Months | 0.3902 | 1.15 | 0.3502 | 0.6320188 | 1,912 | 0.6898 | 176.78% |
1 Year | 0.15 | 1.15 | 0.1425 | 0.3554166 | 3,607 | 0.93 | 620.00% |
3 Years | 0.071 | 1.15 | 0.071 | 0.2159369 | 4,603 | 1.01 | 1,421.13% |
5 Years | 0.017 | 1.15 | 0.0045 | 0.029056 | 37,324 | 1.06 | 6,252.94% |
HST Global (PK) Description
HST Global, a publically held biotechnology and wellness company, discovers and develops breakthroughs in supporting and treating metabolic disorders associated with cancer and other life threatening illnesses. HST Global's new and novel therapeutic approaches positively impact patients with disorders associated with late stage cancer who are in need of supportive well-tolerated treatments. Through its proprietary scientific platform, HST Global is developing therapies that address metabolic deficiencies, dysfunction, or disorders, and provides an alternative source of support for patients. |